Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,310,000 shares, a growth of 22.4% from the March 15th total of 1,070,000 shares. Currently, 16.7% of the company’s shares are short sold. Based on an average trading volume of 115,000 shares, the short-interest ratio is presently 11.4 days.

Institutional Investors Weigh In On Karyopharm Therapeutics

Hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its holdings in shares of Karyopharm Therapeutics by 46.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock valued at $4,274,000 after acquiring an additional 2,000,000 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after purchasing an additional 543,556 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after purchasing an additional 319,187 shares during the period. Shay Capital LLC bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $116,000. Finally, Opti Capital Management LP purchased a new position in Karyopharm Therapeutics during the fourth quarter valued at approximately $85,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on KPTI. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. HC Wainwright boosted their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Finally, Robert W. Baird reduced their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $5.40 on Tuesday. The firm has a market capitalization of $46.28 million, a price-to-earnings ratio of -5.29 and a beta of 0.58. The company has a 50-day moving average of $6.18 and a 200 day moving average of $9.57. Karyopharm Therapeutics has a 1-year low of $3.51 and a 1-year high of $18.00.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).